|Publication number||US4401764 A|
|Application number||US 06/230,477|
|Publication date||Aug 30, 1983|
|Filing date||Feb 2, 1981|
|Priority date||Feb 7, 1980|
|Also published as||CA1149278A, CA1149278A1, DE3164249D1, EP0034050A2, EP0034050A3, EP0034050B1, US4578360|
|Publication number||06230477, 230477, US 4401764 A, US 4401764A, US-A-4401764, US4401764 A, US4401764A|
|Inventors||David S. Smith|
|Original Assignee||Technicon Instruments Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (3), Non-Patent Citations (1), Referenced by (27), Classifications (27), Legal Events (7)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This invention relates to the immunoassay of antigens (which term includes haptens), using a labelled reagent.
Immunoassays which utilize the immunospecific reaction between an antibody and an antigen are well known. It is also known to use in such assays a labelled reagent, part of which becomes bound and part remains free in the reaction mixture, and to determine quantitatively the antibody or antigen under assay by measuring the amount of free or bound labelled reagent. In certain assays of this type, such as radioimmunoassays, it is necessary to separate the bound labelled reagent from the free labelled reagent before measuring the amount of label, and this separation step is not only time-consuming but can be a source of error. Attention has therefore been focussed in recent years on providing an immunoassay in which a separation step is unnecessary, and several workable proposals have been made, including some utilising a fluorophore label.
In fluoroimmunoassays, the amount of bound or free fluorophore-labelled reagent is measured by fluorescence. In the fluoroimmunoassays of certain antigens, the fluorescence of the labelled reagent changes when it becomes bound, so that a separation step is then unnecessary. Such an assay is described in our U.S. Pat. No. 4,150,949 and may be used to assay haptens such as gentamicin. This change in fluorescence does not occur with all antigens, however, and in an alternative approach, the fluorescence of the free fluorophore-labelled reagent in the assay mixture is quenched by introducing the antibody to the fluorophore-label. Thus the antigen to be assayed is mixed with fluorophore-labelled reagent and with antibody to the antigen, and part of the reagent becomes bound and part remains free in the mixture. Antibody to the fluorophore is then added, which binds to the free reagent and changes (usually quenches) the fluorescence thereof. The net resulting fluorescence of the mixture gives a measure of the amount of labelled reagent originally bound to the antibody against the antigen.
While this procedure is satisfactory with certain antigens, the problem arises that in some cases, the antibody to the label will bind not only with the free labelled reagent but also with the bound labelled reagent. We have now devised a way of overcoming this problem.
In one aspect, the present invention provides a method of immunoassay of an antigen (Ag) in a liquid sample, which comprises forming a mixture of:
(b) a substance bearing a non-radiosotopic label, which substance is the same as the Ag under assay or is so closely similar as to be bindable by an antibody against the Ag;
(c) an antibody against the Ag;
and detecting the amount of label activity in the mixture and therefrom determining the amount of Ag; characterised in that: component (c) is a mixed binding reagent which comprises at least one first site selectively bindable to the Ag, and at least one second site selectively bindable to the label, the first and second sites being spaced apart so that a single molecule of labelled substance cannot simultaneously become bound to both a first and a second site, and wherein the activity of the label is changed upon binding to the second sites.
The method of the invention is applicable to assays utilising labels such as fluorophores (or potential fluorophores), spin labels, chemiluminescent labels and, in certain circumstances, enzyme or coenzyme labels. Preferably, however, a fluorophore (or potential fluorophore) label is used and the invention will hereafter be described principally with reference to fluoroimmunoassays, it being understood that in principle and mutatis mutandis other labels such as described may be used. By "potential fluorophore label", we mean a label which does not normally fluorescence but which can be made to fluoresce.
An important feature of the invention is the mixed binding reagent (hereinafter MBR) utilised in step (c). This reagent will normally comprise two antibodies (one against the antigen under assay and the other against the label), the two different antibodies being linked together to form a unitary reagent complex in which the first and second binding sites are spaced apart so that each molecule of the labelled substance can only bind to one site and not simultaneously to both. Thus, in the assay of the invention, the problem encountered in the prior art of a molecule of the labelled substance becoming bound to both types of antibody, is overcome.
The assay of the invention proceeds generally as follows. The sample containing the antigen under assay is mixed with the labelled substance and the MBR. The antigen and the labelled substance compete for the first (i.e. antigen-binding) sites in the MBR. The fluorescence of the labelled reagent is preferably such that it does not change significantly when the substance binds to a first site in the MBR.
The portion of labelled reagent which does not bind to a first site in the MBR is available to bind, via its label, to a second (i.e. label-binding) site in the MBR whereupon its fluorescence will change markedly. Overall, the net resulting fluorescence of the mixture will vary with the amount of Ag present in the original sample, since this affects the amount of labelled reagent both remaining free and becoming bound to second sites in the MBR. By first preparing standard results relating fluorescence to antigen concentration, the amount of antigen in any sample can be determined.
The MBR is an important feature of the present invention. It comprises two different types of binding site which are spaced apart so as to prevent a molecule of the bifunctional labelled substance becoming bound to both types of site. The binding sites themselves are most preferably provided by antibodies or by fragments of antibodies containing their binding sites, although one or both sites may be provided in the form of active chemical groups other than an antibody. A convenient and preferred MBR comprises an antibody to the antigen (to provide first sites), and an antibody to the label (to provide second sites), the two antibodies being linked together in a manner such as to achieve the desired spacing. In one convenient type of MBR, the two antibodies providing the binding sites are linked by a "second" antibody. Thus, the two binding site-antibodies are raised in the same animal species (e.g. rabbit) and are then linked by an antibody (the "second" antibody) to the immunoglobulin of that species (e.g. by sheep (anti-rabbit Ig) antibodies). In this way, the two rabbit-generated antibodies are so located that their respective binding sites for the antigen and label are spaced so that a molecule of labelled substance cannot simultaneously bind to both sites.
The second antibody is only one of the various ways in which the antigen-binding and label-binding antibodies (or other binding substances) can be linked to form an MBR Another possibility is to use protein A in place of the second antibody. Alternatively, both the antigen-binding and the label-binding antibodies can be conjugated with a hapten (or, more generally, an antigen), and then bound by the addition of an antibody to the hapten. Using this technique, it is not necessary for the antigen-binding and label-binding antibodies to have been raised in the same animal species.
Another possibility is for the two antibodies to be linked to a solid substrate. A particularly preferred such substrate is polyacrylamide beads which are known for use in fluoroimmunoassays, and which have a specific gravity close to 1 and also a refractive index close to that of water so that they do not seriously interfere with the fluorescence measurement by light scattering. Such beads are commercially available. By activating the surfaces of the beads, the two antibodies can be covalently or otherwise bound thereto to provide an MBR for use in the present invention.
Another way of preparing an MBR is to link the two antibodies together using a bifunctional chemical bridging group of an appropriate kind, many of which are well known in protein chemistry.
The preferred fluorophore labels are fluorescein, dansyl, rhodamine, fluorescamine, pyrene, 2-methoxy-2,4-diphenyl-3(2H)-furanone, and umbelliferone and derivatives thereof. Of these, fluorescein is the most preferred. The label must be one whose activity (e.g. fluorescence) is changed upon binding to a second site.
The method of the present invention is widely applicable to the assay of antigens, but it is particularly of interest in the assay of haptens, such as gentamicin and similar aminoglycoside antibiotics, and phenytoin and nortriptyline and similar drugs. It can also be used for the assay of thyroid hormones such as thyroxine (T4), although normally in the assay of human sera for T4 or nortriptyline, there will be significant fluorescence interference unless the serum is first treated to remove the interferants.
The nature of the labelled substance is not critical except that it must be bindable by the antibody against the antigen under assay, and also the fluorescence (or other activity) of the label must change when the label binds to the anti-label binding sites in, for example, an antibody. Generally, the substance will be the same as the antigen under assay, but where it is difficult to bind a label to the antigen, then another substance is used which is sufficiently similar to the antigen to bind to the antigen binding sites in the MBR.
The method of the invention may be carried out on a discrete manual basis, or in an automated fashion on a plurality of samples using, for example, the well known continuous flow techniques. In continuous flow analyses according to the present invention, the mixture of sample, fluorescent labelled substance and MBR, is passed along a conduit and the fluorescence is then measured. In a preferred procedure, which is described in U.S. Pat. No. 2,797,149, individual segments of mixture are passed sequentially along the conduit, separated by an inert fluid segment (e.g. air) and, if desired, a wash liquid segment. The mixture can be formed in the conduit itself, by supplying to the conduit, in phase with segments of components of the mixture already present therein, the one or more further components, mixing of the components occurring in the conduit as the mixture flows therethrough.
The following experimental results illustrate the method of the invention.
L-T4, as the free acid, was obtained from Sigma and labelled with fluorescein isothiocyanate as described in our copending U.K. application No. 38710/76 Rabbit anti-fluorescein serum and sheep anti-rabbit immunoglobulin G serum were prepared by standard methods. Rabbit and sheep anti-T4 sera were obtained from Dr. G. Zborowski (Technicon Instruments Corp., Tarrytown, N.Y., U.S.A.) and Dr. T. G. Merrett (Benenden Chest Hospital, Cranbrook, Kent, U.K.), respectively.
All experiments were performed using 75 mmol/l barbital buffer, pH 8.6 at ambient temperature.
Fluorescence was measured using a Perkin-Elmer Model 1000 fluorimeter, fitted with appropriate filters. In the experiments a correction was made for the background signal contributed by reactants other than fluorescein-labelled T4. This was determined by fluorimetry of incubation mixtures containing no labelled hormone. Results were expressed relative to an arbitrary scale of fluorescence intensity.
Fluorescence of labelled T4 in presence of antibody excess
To 500 μl of fluorescein-labelled T4 (30 μg/l) was added 500 μl of antiserum, control serum or buffer, followed after at least 5 min by the addition of 500 μl of a different antiserum, control serum or buffer. Fluorescence was determined as above. Rabbit anti-fluorescein and rabbit control serum were present at a final dilution of 1:6400 and sheep anti-T4 serum and sheep control serum at a final dilution of 1:400.
Fluorescence of labelled T4 in the presence of doubling antiserum dilutions
To 500 μl aliquots of doubling dilutions of rabbit anti-T4, sheep anti-T4, rabbit anti-fluorescein and control sera from sheep and rabbits was added 1 ml of fluorescein-labelled T4 (15 μg/l). Fluorescence was determined after an incubation period of at least 5 min.
Formation of mixed binding reagent
To 500 μl aliquots of doubling dilutions of sheep anti-rabbit immunoglobulin G serum was added 500 μl of a mixture of rabbit anti-T4 and rabbit anti-fluorescein serum. After 60 min, 500 μl of fluorescein-labelled T4 (30 μg/l) was added and the fluorescein measured as above.
Fluoroimmunoassay of the invention using a mixed binding reagent
The mixed binding reagent was first prepared as above. To 100 μl of aliquots of standard solutions of T4 in buffer was added 650 μl of fluorescein-labelled T4 (23 μg/l) followed by 750 μl of the mixed antibody complex and the fluorescence was then determined as above. A control experiment was performed in an identical manner except that a sheep control serum was used in place of the sheep anti-rabbit immunglobulin G serum.
Fluorescence of labelled T4 in the presence of antibody excess
The results are summarised in Table 1. Addition of sheep anti-T4 serum in place of buffer resulted in the expected enhancement of fluorescence (from 16 to 42 fluorescence units) which was not affected significantly by the presence of rabbit control serum. Conversely, addition of rabbit anti-fluorescein serum in place of buffer caused a marked decrease in fluorescence (from 16 to 2 fluorescence units) unaffected by sheep control serum. Irrespective of the order of addition, the fluorescence of fluorescein-labelled T4 was largely quenched in the presence of both the anti-T4 and anti-fluorescein sera, relative to the signal when bound by antibodies to T4 alone. In all cases the reaction was complete within 1 min as judged by attainment of stable fluorescent read-out.
Fluorescence of labelled T4 in the presence of doubling antiserum dilutions
Rabbit anti-T4 and rabbit anti-fluorescein dilution curves were obtained in order to choose appropriate dilutions of these antisera for use in forming the mixed binding reagent. A sheep anti-T4 dilution curve was also obtained and the results are shown in FIG. 2, together with the results using control rabbit and sheep sera. Binding of fluorescein-labelled T4 by antibodies to T4 and to fluorescein resulted in the expected enhancement and quenching of fluorescence, respectively. Non-specific effects were negligible. On the basis of these studies a final dilution of rabbit anti-T4 of 1:1600 and of rabbit anti-fluorescein of 1:6400 was chosen to form the mixed anti-body reagent.
Formation of mixed binding reagent
The fluorescence of fluorescein-labelled T4 added to a mixture of rabbit anti-T4 and anti-fluorescein sera was increased some two-fold by prior complexation of the antibodies with sufficient amounts of sheep anti-rabbit immunoglobulin G serum (FIG. 3). On the basis of this experiment a final dilution of sheep antiserum of 1:160 was chosen to form the mixed binding reagent. Prior incubation of the two rabbit antisera with serum from a control sheep had no significant effect.
Fluoroimmunoassay of the invention using mixed binding reagent
Using the mixed binding reagent, a standard curve for T4 was obtained (FIG. 4) with the addition of increasing amounts of unlabelled T4 causing a progressive decrease in the final fluorescence reading The control experiment confirmed the dependence of the observed effects on the presence of specific sheep anti-rabbit immunoglobulin G serum.
The background signal from reagents other than the labelled T4 was 10 units and was largely contributed by the intrinsic fluorescence of the relatively high concentration of sheep antiserum present. The standard curve obtained employing a mixed binding reagent 24h after preparation was the same as that obtained after 60 min although the mixed binding reagent had developed visible turbidity and the background signal had increased to 12 fluorescence units.
TABLE 1______________________________________Fluorescence of Fluorescein-labelledT4 in the Presence of Antibody ExcessOrder of Reagent Addition to Labelled T4 FluorescenceFirst Reagent Second Reagent Intensity______________________________________Buffer Buffer 16Anti-T4 serum* Buffer 42Anti-T4 serum Rabbit control serum 41Anti-fluorescein serum Buffer 2Anti-fluorescein serum Sheep control serum 2Anti-fluorescein serum Anti-T4 serum 6Anti-T4 serum Anti-fluorescein serum 10______________________________________ *The antiserum dilutions employed are given in the methods section
The following reagents were used: rabbit anti-fluorescein serum; rabbit anti-amikacin serum; sheep anti-rabbit immunoglobulin G serum; and fluorescein-labelled amikacin prepared by the reaction of amikacin with fluorescin isothiocyanate. The buffer used was 100 mmol/l sodium phosphate, pH 7.5, containing 1 ml/l Triton X-100 detergent and 1 g/l sodium azide.
Formation of mixed binding reagent
To a mixture of anti-fluorescein serum and anti-amikacin serum was added anti-rabbit immunoglobulin G serum, so as to give final dilutions of the antisera as follows: anti-amikacin 1:320; anti-fluorescein 1:2,000; and anti-rabbit immunoglobulin G 1:40. The mixture was left at room temperature for 1 hour before use.
To 50 μl aliquots of standard solutions of amikacin in buffer was added 750 μl of fluorescein-labelled amikacin (20 nmol/l concentration estimated spectrophotometrically), followed by 750 μl of mixed binding reagent. After incubation for 30 min at room temperature, the fluorescence of the mixtures was determined. Correction was made for the background signal contributed by reactants other than fluorescein-labelled amikacin; this was determined by measurement of the fluorescence of mixtures containing no labelled antibiotic. Results were expressed relative to an arbitrary scale of fluorescence intensity. The standard curve obtained is shown in FIG. 5.
In the accompanying drawings:
FIGS. 1A and 1B are a diagrammatic representation of one embodiment of the method of the invention as applied to fluoroimmunoassays. In FIGS. 1A and 1B, the mixed binding reagent 1 has anti-hapten binding sites 2 and anti-label binding sites 3. In FIG. 1A, the hapten 5 carries a fluorescein label 6. In FIG. 1B, some of the hapten 5 is labelled and some is not. In FIG. 1A, when the labelled hapten is incubated with the MBR 1, some of the labelled hapten will be bound to the anti-hapten sites 2 and continue to fluoresce, while some will be bound by the anti-fluorescein sites 3 with a resultant decrease in fluorescence. In FIG. 1B unlabelled hapten is also present in the reaction mixture. This competes with labelled hapten for anti-hapten binding sites 2, and as more labelled hapten becomes bound to anti-fluorescein sites 3, there will be a further decrease in fluorescence. Thus the fluorescence of the incubation mixtures at equilibrium will be inversely related to the initial amount of unlabelled hapten present.
FIG. 2 shows anti-T4 and anti-fluorescein dilution curves. Closed circles, sheep anti-T4 serum; open circles, rabbit anti-T4 serum; closed triangles, control sheep serum; open triangles, control rabbit serum; closed squares, anti-fluorescein serum.
FIG. 3 is an anti-immunoglobulin G dilution curve in formation of mixed antibody reagent. Final dilutions: anti-T4 serum 1:1600; anti-fluorescein serum 1:6400. Open circle shows fluorescence in absence of added anti-immunoglobulin G serum.
FIG. 4 is the fluoroimmunoassay standard curve. Closed circles, using mixed binding reagent; open circles, anti-immunoglobulin G serum replaced by control sheep serum. Final dilutions: anti-T4 serum 1:1600; anti-fluorescein serum 1:6400; anti-immunoglobulin G serum or control sheep serum 1:160.
FIG. 5 is the fluoroimmunoassay standard curve for the assay of amikacin.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3996345 *||Jun 30, 1975||Dec 7, 1976||Syva Company||Fluorescence quenching with immunological pairs in immunoassays|
|US4108976 *||Mar 4, 1977||Aug 22, 1978||Becton, Dickinson And Company||Automated direct serum radioimmunoassay|
|US4161515 *||Dec 17, 1976||Jul 17, 1979||Syva Company||Double receptor fluorescent immunoassay|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US4689311 *||Sep 30, 1985||Aug 25, 1987||Rhode Island Hospital||Screening antibodies for capacity to deliver toxin to target cells|
|US4778751 *||May 12, 1986||Oct 18, 1988||Diagnostic Products Corporation||Method for measuring antigens or antibodies in biological fluids using ligand labeled antigens or ligand labeled antibodies|
|US5086002 *||Mar 16, 1989||Feb 4, 1992||Agen Biomedical, Ltd.||Erythrocyte agglutination assay|
|US5116724 *||Sep 29, 1988||May 26, 1992||Immunotech||Products for separation applicable to cells in the immunopurification field|
|US5130234 *||Aug 28, 1989||Jul 14, 1992||Iatron Laboratories, Inc.||Method of quantitative determination utilizing enzyme aggregation|
|US5246829 *||Mar 10, 1992||Sep 21, 1993||Immunotech||Products for separation applicable to cells in the immunopurification field|
|US5256395 *||Sep 10, 1987||Oct 26, 1993||Immunotech Partners||Affinity enhancement immunological reagents for in vivo detection and killing of specific target cells|
|US5340748 *||May 25, 1993||Aug 23, 1994||Abbott Laboratories||Analyte-substitute reagent for use in specific binding assay methods, devices and kits|
|US5413913 *||Feb 3, 1994||May 9, 1995||Agen Biomedical, Ltd.||Erythrocyte agglutination assay|
|US5583003 *||Nov 30, 1994||Dec 10, 1996||Agen Limited||Agglutination assay|
|US6867005||Oct 24, 2001||Mar 15, 2005||Beckman Coulter, Inc.||Method and apparatus for increasing the dynamic range and accuracy of binding assays|
|US7888003||Sep 2, 2005||Feb 15, 2011||The United States Of America As Represented By The Department Of Health And Human Services||Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein|
|US8722324||Dec 23, 2010||May 13, 2014||The United States Of America, As Represented By The Secretary Department Of Health And Human Services||Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides|
|US9121855||Dec 23, 2010||Sep 1, 2015||The United States Of America, As Represented By The Secretary, Department Of Health And Human Services||Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope|
|US20100068823 *||Jun 21, 2006||Mar 18, 2010||Thomas Ehben||Carrier Material, Method for the Production and Use Thereof|
|US20110151436 *||Dec 23, 2010||Jun 23, 2011||The Government of the United States of America as represented by the Secretary, Dept. of Health||Compositions and methods for the detection of hiv-1/hiv-2 infection|
|US20110201035 *||Dec 23, 2010||Aug 18, 2011||The United States Of America As Represented By The Secretary Of Health And Human Services, Nih||Compositions and methods for the detection of hiv-1/hiv-2 infection|
|EP2295973A1||Sep 2, 2005||Mar 16, 2011||THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services||Compositions and methods for the detection of HIV-1/HIV-2 infection.|
|EP2295974A1||Sep 2, 2005||Mar 16, 2011||THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES||Compositions and methods for the detection of HIV-1/HIV-2 infection|
|EP2309269A1||Sep 2, 2005||Apr 13, 2011||THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES||Compositions and methods for the detection of HIV-1/HIV-2 infection.|
|EP2492279A1||Feb 25, 2011||Aug 29, 2012||Laboratorios Del. Dr. Esteve, S.A.||Rapid immunogen selection method using lentiviral display|
|EP2698377A1||Aug 17, 2012||Feb 19, 2014||Laboratorios Del. Dr. Esteve, S.A.||Enhanced rapid immunogen selection method for HIV gp120 variants|
|WO1986001407A1 *||Aug 23, 1985||Mar 13, 1986||Hybritech Incorporated||Monoclonal antibodies against metal chelates|
|WO1987001941A1 *||Sep 10, 1986||Apr 9, 1987||Rhode Island Hospital||Composition containing toxin linked to an antigen non-specific antibody|
|WO2010135663A2||May 21, 2010||Nov 25, 2010||The United States Of America , As Represented By The Secretary, Department Of Health And Human Services||Compositions and methods for the detection of hiv-1/hiv-2 infection|
|WO2012113921A1||Feb 24, 2012||Aug 30, 2012||Laboratorios Del Dr. Esteve, S.A.||Rapid selection method for hiv gp-120 variants|
|WO2014027082A1||Aug 16, 2013||Feb 20, 2014||Laboratorios Del Dr. Esteve, S.A.||Enhanced rapid immunogen selection method for hiv gp120 variants|
|U.S. Classification||436/500, 436/532, 436/815, 436/828, 436/547, 436/805, 436/531, 436/819, 436/533, 436/534, 436/546|
|International Classification||G01N33/542, G01N33/531, G01N33/78, G01N33/543|
|Cooperative Classification||Y10S436/805, Y10S436/819, Y10S436/815, Y10S436/828, G01N33/78, G01N33/542, G01N33/531, G01N33/54306|
|European Classification||G01N33/543B, G01N33/531, G01N33/542, G01N33/78|
|Oct 21, 1981||AS||Assignment|
Owner name: TECHNICON INSTRUMENTS COMPANY LIMITED
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SMITH, DAVID S.;REEL/FRAME:003918/0412
Effective date: 19810930
|May 13, 1983||AS||Assignment|
Owner name: TECHNICON INSTRUMENTS CORPORTION, TARRYTOWN, N.Y.,
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:TECHNICON INSTRUMENTS COMPANY LIMITED;REEL/FRAME:004126/0209
|Jan 27, 1987||FPAY||Fee payment|
Year of fee payment: 4
|Feb 27, 1987||FPAY||Fee payment|
Year of fee payment: 4
|Jul 5, 1988||AS||Assignment|
Owner name: TECHNICON INSTRUMENTS CORPORATION
Free format text: MERGER;ASSIGNOR:REVGROUP PANTRY MIRROR CORP.;REEL/FRAME:004912/0740
Effective date: 19871231
|Oct 30, 1990||FPAY||Fee payment|
Year of fee payment: 8
|Feb 3, 1995||FPAY||Fee payment|
Year of fee payment: 12